FY2024 Earnings Estimate for uniQure Issued By HC Wainwright

uniQure (NASDAQ:QURE) – Stock analysts at HC Wainwright lowered their FY2024 earnings per share (EPS) estimates for uniQure in a research note issued to investors on Monday, January 27th. HC Wainwright analyst P. Trucchio now anticipates that the biotechnology company will post earnings per share of ($4.17) for the year, down from their prior estimate of ($4.16). HC Wainwright has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.74) per share. HC Wainwright also issued estimates for uniQure’s Q4 2024 earnings at ($0.75) EPS, Q1 2025 earnings at ($0.66) EPS, Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.75) EPS, Q4 2025 earnings at ($0.85) EPS, FY2025 earnings at ($2.99) EPS, FY2026 earnings at ($1.80) EPS, FY2027 earnings at $6.91 EPS and FY2028 earnings at $16.97 EPS.

Several other equities analysts also recently commented on the company. The Goldman Sachs Group upped their price objective on uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 12th. Guggenheim reaffirmed a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. StockNews.com raised uniQure to a “sell” rating in a report on Wednesday, December 11th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $24.00 price objective on shares of uniQure in a report on Tuesday, January 21st. Finally, Stifel Nicolaus increased their target price on shares of uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, December 16th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $40.00.

uniQure Stock Down 0.5 %

QURE opened at $15.24 on Wednesday. The company’s 50-day moving average price is $13.31 and its two-hundred day moving average price is $8.84. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a twelve month low of $3.73 and a twelve month high of $19.18. The stock has a market cap of $742.80 million, a price-to-earnings ratio of -3.07 and a beta of 0.41.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating the consensus estimate of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The company had revenue of $2.29 million during the quarter, compared to analyst estimates of $2.73 million.

Insider Activity

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the transaction, the chief executive officer now directly owns 597,915 shares in the company, valued at $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.74% of the stock is owned by company insiders.

Institutional Trading of uniQure

Several institutional investors and hedge funds have recently modified their holdings of QURE. China Universal Asset Management Co. Ltd. increased its position in shares of uniQure by 9.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 969 shares during the last quarter. Sanders Morris Harris LLC grew its stake in uniQure by 50.0% in the 4th quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company’s stock worth $1,803,000 after buying an additional 34,034 shares in the last quarter. FNY Investment Advisers LLC bought a new position in shares of uniQure in the 4th quarter worth $88,000. Franklin Resources Inc. purchased a new stake in shares of uniQure during the 3rd quarter valued at $7,360,000. Finally, Geode Capital Management LLC lifted its holdings in shares of uniQure by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock worth $2,509,000 after acquiring an additional 6,362 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.